CD19 and neoplasm: The studies have shown that in a high-disease burden setting, the bispecific CD19-CD20 CARs CAR proved both effective and less toxic than single CARs in pre-clinical settings(33, 34) Similarly, bispecific CAR has been designed to target both human epidermal growth receptor 2 (HER2) and IL13Rα2 and it showed enhanced potency and anti-tumor activity in vivo compared to two separate CARs (35).